Rapt Therapeutics Inc RAPT

Healthcare Biotechnology

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.

NDAQ:RAPT - Post by User

Rapt Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by AviseAnalyticson Oct 12, 2021 8:11am

92 Views

Post# 33996443

4 BIOTECH STOCKS INSIDERS ARE SELLING!

$RAPT $DCPH $FGEN $SGTX

Insider selling cannot be the sole indicator for investing in a stock, but it would be wise to make a note of the buying and selling activities to gauge a company’s prospects or the lack thereof.

While insiders buying or selling the Company’s stock could provide investors with a general idea about the direction it is headed, a thorough understanding of its fundamentals, recent news and analyst estimates should be taken into consideration while making an investment decision.

We take a look at four companies that have witnessed insider selling in the past year.

Read more
https://www.aviseanalytics.com/4-biotech-stocks-insiders-are-selling/

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant